Aleos Capital Invests in Eggnovo, Launches Fund I

Aleos Capital, a private equity firm with a strategic focus on life sciences, has initiated its investment activities by securing a majority stake in Eggnovo, a Spanish innovator in natural ingredient extraction. This pivotal transaction represents the first deployment from Aleos Fund I, signaling the firm's entry into the competitive investment arena.

Eggnovo, based in Spain, has carved a niche by deriving high-value bioactive compounds, such as collagen, hyaluronic acid, and elastin, from eggshell membranes. These specialized ingredients serve a diverse range of sectors, including nutraceuticals, cosmetics, veterinary applications, and the broader food industry. The company's robust growth is underscored by revenues surpassing €10 million, with impressive annual expansion rates exceeding 30% observed between 2020 and 2025, indicating strong market demand for its sustainable offerings.

The establishment of Aleos Fund I, targeting between €150 million and €200 million, reflects a clear strategy to capitalize on high-growth opportunities. The fund's investment thesis centers on companies operating within the health and wellness, sustainable nutrition, and climate and environmental technology domains. Initially concentrating on the Iberian Peninsula (Spain and Portugal), Aleos Capital has articulated ambitions for future expansion into wider Southern European and Latin American markets.

This strategic investment by Aleos Capital is designed to significantly accelerate Eggnovo's expansion initiatives. Key objectives include bolstering international market penetration, reinforcing its competitive standing within the rapidly expanding natural ingredients sector, and potentially exploring synergistic acquisitions. The increasing consumer preference for clean-label, ethically sourced, and scientifically validated bioactive components fuels the market's upward trajectory.

The market for eggshell membrane-derived ingredients is experiencing considerable momentum. Driven by a global shift towards natural and sustainable product formulations, particularly in beauty-from-within and functional food categories, the demand for such specialized biomaterials is projected to climb. Industry analysts estimate the global market for cosmetic ingredients derived from natural sources to reach tens of billions of dollars in the coming years, with significant growth in specialized segments like collagen and hyaluronic acid.

Founded by seasoned professionals with prior experience at prominent firms like Alantra and Apax Partners, Aleos Capital brings a wealth of expertise to its portfolio companies. The firm's deep understanding of the life sciences and sustainable industries positions it to provide strategic guidance and operational support, aiming to unlock significant value for its investors and portfolio partners. The successful structuring of Aleos Fund I and the initial acquisition were facilitated by legal counsel from Addleshaw Goddard.